About Us

At Highland Therapeutics we invest in proprietary drug-delivery technologies to develop improved versions of existing drug products.

What We Do

Highland Therapeutics is the parent company of two wholly owned subsidiaries: Ironshore Pharmaceuticals & Development, Inc. based in the Cayman Islands and Ironshore Pharmaceutics Inc. based in the United States.

Highland Office

Highland Therapeutics Inc.

MaRS Centre, West Tower
661 University Ave, Suite 415
Toronto ON, M5G 1M1


David Lickrish
Chief Executive Officer

David Lickrish

David Lickrish is the co-inventor, founding shareholder and Chief Executive Officer of Highland Therapeutics.

Under his leadership, Ironshore has grown from a start-up company, founded in the midst of the financial crisis, to an international pharmaceutical company with a proprietary drug-delivery technology and an FDA-approved product since 2018.

Mr. Lickrish studied Microbiology and Finance at the University of Guelph in Canada. He graduated with Honors and received his Bachelor of Commerce in International Economics and Finance. Mr. Lickrish has been a CFA Charter holder since 2001 and has worked internationally covering the Global Pharmaceutical Industry as Senior Vice President of Equity Research.

Nelson Isabel

Nelson Isabel serves as the Vice President, Finance, for Ironshore Pharmaceuticals & Development, Inc.

Prior to joining Ironshore, Mr. Isabel spent seven years at Biovail Corporation (now Bausch Health), Canada's largest publicly traded pharmaceutical company, where he served on its Finance Leadership Team and was responsible for all investor relations and corporate communication activities. Prior to Biovail, Mr. Isabel was an equity research analyst covering the Canadian healthcare industry with CIBC World Markets and with Desjardins Securities.

Mr. Isabel has a B.Sc. in Experimental Animal Physiology and a Master of Business Administration from the Schulich School of Business in Toronto. He has been a CFA Charter holder since 2002.